Compare BY & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | NVAX |
|---|---|---|
| Founded | 1914 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2017 | 1996 |
| Metric | BY | NVAX |
|---|---|---|
| Price | $37.55 | $8.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $36.00 | $11.33 |
| AVG Volume (30 Days) | 271.4K | ★ 4.4M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | 5.09 | ★ 309.76 |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $16.89 | N/A |
| Revenue Next Year | $3.15 | N/A |
| P/E Ratio | $44.33 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $25.38 | $6.20 |
| 52 Week High | $36.90 | $11.85 |
| Indicator | BY | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 76.53 | 46.20 |
| Support Level | $32.02 | $8.89 |
| Resistance Level | N/A | $9.02 |
| Average True Range (ATR) | 0.68 | 0.60 |
| MACD | 0.19 | -0.08 |
| Stochastic Oscillator | 86.53 | 36.52 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through a wholly-owned subsidiary of Byline Bank.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.